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eyes with neovascular age-related macular degeneration are limited by the time span from death to
preservation and the associated 50-RNA degradation. This study therefore used CNV and control specimens
that were formalin-fixed and paraffin-embedded immediately after surgical extraction and analyzed them
by a 30-RNA sequencing approach. Transcriptome profiles were analyzed to estimate content of immune
and stromal cells and to define disease-associated gene signatures by using statistical and bioinformatics
methods. This study identified 158 differentially expressed genes (DEGs) that were significantly increased
in CNV compared with control tissue. Cell type enrichment analysis revealed a diverse cellular landscape
with an enrichment of endothelial cells, macrophages, T cells, and natural killer T cells in the CNV. Gene
ontology enrichment analysis found that DEGs contributed to blood vessel development, extracellular
structure organization, response to wounding, and several immune-related terms. The S100 calcium-
binding proteins A8 (S100A8) and A9 (S100A9) emerged among the top DEGs, as confirmed by immu-
nohistochemistry on CNV tissue and protein analysis of vitreous samples. This study provides a high-
resolution RNA-sequencingebased transcriptional signature of human CNV, characterizes its composi-
tional pattern of immune and stromal cells, and reveals S100A8/A9 to be a novel biomarker and promising
target for therapeutics and diagnostics directed at age-related macular degeneration. (Am J Pathol 2020,
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Disclosures: None declared.Choroidal neovascularization (CNV) is a common cause of
irreversible vision loss in patients with age-related macular
degeneration (AMD), which is the leading cause of blindness
in the elderly, affecting approximately 200 million in-
dividuals worldwide.1 The introduction of antiangiogenic
therapy has enabled significant advances in the treatment
of neovascular AMD (nAMD). However, the treatment’s
success is hampered by the relatively short half-life of
antibodies in the eye and depends on frequently repeated
intraocular injections that pose a significant cumulative risk of
local complications. Approximately one-third of patients withstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgnAMD lose vision despite continuous antievascular endo-
thelial growth factor therapy,2 highlighting the complexity of
this disease and indicating a relevance of other disease-
associated molecular mediators..
/licenses/by-nc-nd/4.0).
Characterization of Human CNV MembranesAlthough genome-wide association studies, animal
models, and cell culture systems have provided important
insights into nAMD pathogenesis, the underlying cellular and
molecular mechanisms in the cascade of events leading to
CNV have not been identified in detail. Risk factors for
nAMD include increasing age, environmental factors such as
smoking, and dietary habits, as well as mutations in sus-
ceptibility genes, which predispose an individual to devel-
oping AMD. Most AMD gene-association studies published
thus far are genome-wide association studies investigating
single nucleotide polymorphisms or noncoding single
nucleotide polymorphisms associated with CNV formation.
These studies have identified several risk factors, such as
polymorphisms in the CFH, ARMS2, or C3 genes,3 but they
do not provide a detailed view on the biological pathways
underlying CNV formation. Gene expression studies on
human CNV membranes are therefore becoming increasingly
important to move beyond genetic association and compre-
hensively uncover CNV-associated pathways.4
To that end, numerous studies have used microarray tech-
nology to explore the expression profiles of normal human eye
tissues5,6 and to determine genes differentially expressed in
eyes of patients with nAMD.7 Those studies, however, were
limited by their dependence on the standard genome annota-
tions required for probe design and possible cross-
hybridization problems.8 The more recent availability of
RNA-sequencing (RNA-Seq) techniques improved examina-
tion of the transcriptome of healthy and diseased tissues,
enabling a more accurate and unbiased measurement of gene
expression abundance. Moreover, RNA-Seq can assess novel
and particularly rare transcripts that have been overlooked by
conventional microarray technology so far, and it is also more
reproducible due to less technical variation and fewer false-
positive findings.9,10 All previously published microarray
and RNA-Seq studies on CNV membranes, however, are
limited by the fact that they have been performed on human
donor eyes.7,11e14 Because the postmortem interval and the
time from death to conservation may range from at best 1 hour
to well over 24 hours,15 it can be assumed that the RNA is
already partially degraded. This scenario is particularly critical
given the short half-life of mRNA, which ranges between 10
and 25 minutes.16 Although retinal tissue can provide stable
RNA, if processed within 5 hours after death, the retinal
pigment epithelium (RPE), which is one of the tissues pri-
marily affected in AMD, must be processed immediately to
prevent its decay.17 To overcome this limitation, the current
study analyzed CNVmembranes that had been formalin-fixed
and paraffin-embedded (FFPE) immediately after surgical
extraction from patients with nAMD. Because RNA degra-
dation in FFPE samples is subjected to chemical degradation,
which occurs from 50 to 30 ends,18 a 30-end RNA sequencing
approach called Massive Analysis of cDNA Ends (MACE)
was used. This approach allows deciphering of expression
signatures, assessment of differential expression,19 and esti-
mation of the compositional patterns of immune and stromal
cells in CNV using the computational method xCell.20The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Study Population
This study included 11 patients with nAMD and 18 control
patients. For RNA-Seq analysis of human CNV membranes,
we retrospectively analyzed four consecutive patients with
nAMD who underwent subretinal CNV extraction during
vitreoretinal surgery between 1992 and 1999. All CNV
membranes were treatment-naive classic CNV and were
processed for formalin fixation and paraffin embedding
immediately following extraction. Four age-matched FFPE
RPE/choroidal specimens obtained in the same period from
the macular region of enucleated eyes with ciliary body
melanoma served as control samples (Figure 1). For immu-
nohistochemical analysis, the aforementioned FFPE CNV
membranes and three randomly chosen and macroscopically
normal eyes of three body donors admitted to the Institute of
Anatomy were analyzed. Eyes were enucleated in consent
with the body donors and secured by contract; no data other
than age, sex, weight, and cause of death were disclosed.
For protein quantification, seven consecutive patients with
nAMD and 11 patients without AMD who underwent vit-
rectomy for subretinal bleeding or macular pucker between
2017 and 2019 were enrolled. Patients with vitreous hem-
orrhage, history of previous vitreoretinal surgeries, intraoc-
ular inflammations, or concomitant vitreoretinal diseases
were excluded. Ethics approval was granted from the Ethics
committee of the University of Freiburg, and written
informed consent was obtained from each patient.Sample Collection and Preparation
CNV membranes for RNA-Seq were obtained from four
patients by using the currently obsolete technique of sub-
retinal CNV extraction.21 Following a 20-gauge vitrectomy,
retinotomy was performed temporal to the macula, and the
CNV membrane was surgically extracted by using a flexed
forceps. The diagnosis was made after a thorough fundu-
scopic examination of both eyes. Only patients exhibiting a
CNV associated with AMD changes, such as drusen and
RPE alterations, were included in the study. CNV mem-
branes from patients with other diseases (eg, myopia, his-
tory of central serous chorioretinopathy) were not included
in this study. Control RPE/choroid samples for RNA-Seq
were obtained from the macula region of four enucleated
eyes with ciliary body melanoma.
For protein analysis, undiluted vitreous samples (0.5 to 0.8
mL) were obtained from the mid-vitreous of 7 patients with
nAMD and 11 patients with epiretinal membrane (control)
undergoing vitrectomy using a vitreous cutter at the start of a
vitrectomy, before intraocular infusion of fluid. Plasma
samples (2 mL) were collected by venous puncture from the
same patients after surgery. The vitreous and plasma samples
were transferred directly into sterile plastic tubes on ice. The
samples were aliquoted and stored at 80C until analysis.1633
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Figure 1 Study subjects and experimental setup for the transcriptional analysis of human choroidal neovascularization (CNV) membranes and control
samples. Study subjects were diagnosed after a thorough funduscopic examination. Following surgical CNV excision, the tissue was formalin-fixed and
paraffin-embedded (FFPE) before histologic analysis was performed. RNA sequencing was conducted on CNV membranes and healthy retinal pigment
epithelium (RPE)/choroid tissue samples (control [Ctrl]) obtained from enucleated eyes (boxed area) using the Massive Analysis of cDNA Ends (MACE)
technology. Different colors represent transcripts of different genes, and the respective data were bioinformatically analyzed. Scale bars Z 20 mm.
Schlecht et alParaffin Embedding
Formalin fixation and paraffin embedding of CNV mem-
branes and control RPE/choroidal tissue was performed
immediately after surgery according to routine protocols, as
previously described.19 Briefly, specimens were fixed
immediately after surgery in 4% formalin for 12 hours,
dehydrated in alcohol, and finally processed for paraffin
embedding. Sections were cut (4-mm thick), mounted on
silanized slides, and deparaffinized in xylol-alcohol. After
routine histologic staining, each specimen’s histologic diag-
nosis was made by two experienced ophthalmic pathologists.RNA Isolation
Fifteen FFPE sections (4-mm thick) from each CNV mem-
brane were collected and stored in tubes before RNA
extraction. For the initial histopathologic evaluation, FFPE
eyes of patients with ciliary body melanoma had been
dissected by removing two scleral shells, leaving a central
sclerocorneal ring segment. For the current study, the FFPE
blocks were melted, and using a dissection microscope, the
retina was carefully lifted off the RPE layer. Next, the RPE
and choroid were cut laterally with a scalpel, and the central
RPE/choroid complex, which easily detaches from the sclera
in FFPE eyes, was retrieved and stored in low binding tubes
until RNA extraction was performed. RNA isolation from
FFPE specimens was performed as previously described.19
Briefly, total RNA was extracted from FFPE samples by
using the Quick-RNA FFPE Kit (Zymo Research, Irvine,
CA). Following DNase I digestion using the Baseline-ZERO
Kit (Epicentre Technologies, Madison, WI), the RNA con-
centration was quantified by using the Qubit RNA HS Assay
Kit on a Qubit Fluorometer (Thermo Fisher Scientific, Wal-
tham, MA). RNA quality was determined via the RNA Pico
Sensitivity Assay on a LabChip GXII Touch (PerkinElmer,1634Waltham, MA). The fragment size of all RNA samples
ranged between 120 and 150 bp.
MACE Libraries
The preparation of MACE libraries was performed by Gen-
XPro GmbH (Frankfurt, Germany) using 1 mg of total RNA
as previously described.19 Briefly, eight barcoded libraries
(four CNV membranes and four RPE/choroidal control tis-
sues) were sequenced simultaneously on the NextSeq 500
(Illumina, San Diego, CA) with 1  75 bp. The sequencing
data reported in the current article have been deposited in the
Gene Expression Omnibus database (https://www.ncbi.nlm.
nih.gov/geo; accession number GSE146887).
Protein Analysis
Vitreous and plasma calprotectin levels were measured on
vitreous and plasma samples from patients with nAMD
undergoing vitrectomy for subretinal macular hemorrhage.
Patients with macular pucker undergoing vitrectomy for
epiretinal peeling served as control subjects. Frozen vitreous
and plasma samples were thawed, and calprotectin levels
were measured by using the Human S100A8/S100A9 Het-
erodimer Quantikine ELISA Kit according to the manu-
facturer’s protocol (R&D Systems, Minneapolis, MN).
Immunohistochemistry
Human choroidal CNVmembranes and control FFPE samples
were cut into 5-mm sections and deparaffinized according to
standard protocol. Sections were blockedwith 5%normal goat
serum in phosphate-buffered saline (PBS)/Triton-X 0.03% for
60 minutes at room temperature. Primary anti-S100 calcium-
binding protein A9 (S100A9) antibody (sc-376772; Santa
Cruz Biotechnology, Dallas, TX) was incubated in a 1:200
dilution in PBS containing 0.5% bovine serum albumin andajp.amjpathol.org - The American Journal of Pathology
Characterization of Human CNV Membranes0.03% Triton-X overnight at 4C. No primary antibody served
as negative control. After extensive washing with PBS/Triton-
X 0.03%, sections were incubated with an Alexa Fluor
647elabeled goat anti-mouse secondary antibody 1:500 in
PBS/Triton-X 0.03% (Thermo Fisher Scientific) at room
temperature for 1 hour in the dark. After washing at least three
times with PBS/Triton-X 0.03% and Aqua Dest, auto-
fluorescence was quenched with Sudan Black B (0.3% in 70%
ethanol overnight, stirring at 50C, filtrated twice, and incu-
bated for 5 minutes at 37C on the slides). Nuclei were
counterstained with DAPI 1:10,000 for 5 minutes, washed
three times with Aqua Dest, and mounted in Fluorescence
Mounting Medium (Agilent Dako, Santa Clara, CA). Slides
were imaged by using an Olympus BX-40 with a color camera
(XM10, Olympus, Tokyo, Japan).
Statistics and Bioinformatics
Sequencing data were uploaded to and analyzed on the Galaxy
web platform (usegalaxy.eu) as previously described.22,23
Quality control was performed with FastQC Galaxy version
0.72 (Barbraham Bioinformatics, Babraham, UK; http://www.
bioinformatics.babraham.ac.uk/projects/fastqc, last accessed
August 5, 2019). Reads were mapped to the human reference
genome (hg38, Galaxy built-in reference genome) with RNA
STAR Galaxy Version 2.6.0b-224 (default parameters) using
the GENCODE annotation file (GENCODE 31, release June
2019, downloaded on August 5, 2019; https://www.
gencodegenes.org/human/releases.html).25 Reads mapped to
the human reference genome were counted by using featur-
eCounts GalaxyVersion 1.6.426 (default parameters) using the
aforementioned annotation file.
The output of featureCounts was imported to RStudio
version 1.2.1335) (R version 3.5.3). Gene symbols and gene
types were determined based on Ensembl release 97
(July 2019) (Human genes, GRCh38.p12, downloaded on
August 31, 2019).27 Genes with 0 reads were removed from
the analysis. Based on Ensembl gene types, genes were
filtered for protein coding genes and small RNAs (long
noncoding RNA, miRNA, miscellaneous RNA, small con-
ditional RNA [scRNA], small nucleolar RNA, snRNA, and
small RNA). Genes coding for ribosomal or mitochondrial
proteins were removed from the analysis. After principal
component analysis, differential gene expression with
Benjamini-Hochberg adjusted (adj.) P values was analyzed
by using the R package DESeq2 version 1.22.2 (default
parameters).28
Transcripts with log2fold change (log2FC) >2 or <2
and Benjamini-Hochberg adj. P < 0.05 were considered as
differentially expressed genes (DEGs). Heatmaps were
created with the R package ComplexHeatmap 1.20.0.29 Data
visualization with volcano plots was performed by using the
ggplot2 package.30 Gene enrichment analysis and its visual-
ization with dotplots and cnetplots were performed by using
the R package clusterProfiler 3.10.1.31 The 10 most signifi-
cant Gene Ontology (GO) terms were visualized by usingThe American Journal of Pathology - ajp.amjpathol.orgdotplots. A cnetplot was used to illustrate the four most
disease-associated GO terms and their associated DEGs.
To determine the cellular profile within the CNV micro-
environment, the computational method xCell, which esti-
mates the abundance scores of 64 immune and stromal cell
types, including hematopoietic progenitors, epithelial cells,
extracellular matrix (ECM) cells, and adaptive and innate
immune cells, was applied.20 Although the final xCell
abundance scores cannot be directly interpreted as cell
fractions, they showed high correlation with the true cell
proportions.32 For xCell analysis, transcripts per million
were calculated based on the output of featureCounts
(assigned reads and feature length), as previously
described.33 Enrichment scores were compared between
different groups by using U-tests. Cell types with P < 0.05
were considered to be significantly differentially enriched.
Results
Patient Characteristics
For MACE RNA-Seq analysis, four eyes of four consecutive
patients with nAMD were included; four eyes of four patients
with ciliary body melanoma requiring enucleation served as
control samples. Three macroscopically normal eyes of three
body donors served as control samples for immunohisto-
chemical analysis. Patients’ mean age was 79.5 years (range,
72 to 83 years) in the nAMDgroup, 73.0 years (range, 66 to 75
years) in the control group, and 82.7 years (range, 78 to
89 years) in the body donor group. CNV membranes were
stored in paraffin for ameanof 7.264 days (range, 4346 to 7848
days) before RNA-Seq, and control samples were stored for
6.197 days (range, 3410 to 8057 days). Routine hematoxylin
and eosin histology confirmed the diagnosis of CNV and
revealed a microscopically intact retinal, RPE, and choroidal
histology in the control and bodydonor samples (Figure 1). For
protein quantification, seven consecutive patients with nAMD
and 11 patients without AMD who underwent vitrectomy for
subretinal bleeding ormacular puckerwere enrolled. Themean
age of patients with nAMD was 77 years (range, 72 to
90 years); the mean age of the control patients was 70 years
(range, 64 to 76 years). None of the patients exhibited
concomitant macular disease, and only two patients with
nAMD had received intravitreal bevacizumab injections
4 months before vitrectomy.
MACE RNA-Seq and Cell Type Enrichment Analysis in
Human CNV
Using MACE RNA-Seq, a mean number of 907.233 reads
(range, 297,004 to 1.744.933) in CNV samples and
4.889.361 reads (range, 348.446 to 11.898.565) in control
samples were obtained. Because the RNA-Seq profile is a
mixture of RNA from multiple cell types that include
resident and infiltrating cells, bulk RNA cell type
enrichment analysis was first used to recover the identity1635
Schlecht et alof the cell types found in human CNV, using the gene
signature expressionebased cell type enrichment tool
xCell.20 Cell type enrichment scores across 64 immune
and stromal cell types were obtained for both CNV and
control specimens (Figure 2A and Supplemental
Figure S1). These data show that immune scores were
overall higher in CNV samples (0.025  0.029) compared
with the scores of healthy RPE/choroid samples
(0.014  0.013; P Z 0.27). Among the different immune
cell subpopulations, CD4 T-effector memory phenotype
cells, CD4þ naive T cells, M1 macrophages, and natural
killer T cells were significantly increased in CNV samples
compared with levels observed in healthy control samples
(P < 0.05) (Figure 2A). In contrast, T helper cells type 2
and basophils were significantly decreased in CNV sam-
ples compared with control samples. Of note, sub-
populations of M2 macrophages were similar in CNV
samples compared with control samples (Supplemental
Figure S1). Overall stroma scores were significantly
different between CNV samples (0.036  0.036)
compared with control samples (0.009  0.008;
P < 0.05). In particular, endothelial cells and microvas-
cular endothelial cells were substantially increased in
CNV samples compared with levels observed in healthy
control samples (P < 0.05) (Figure 2A).
Differential Gene Expression in Human Choroidal
Neovascularization
Of a total 29.334 different RNA transcripts, five differen-
tially expressed transcripts that were decreased in CNV
samples and 158 differentially expressed transcripts that
were increased in CNV membranes compared with control
samples (ie, log2FC > 2 or < 2; adj. P < 0.05) were
determined. The top five differentially overexpressed tran-
scripts in CNV membranes included the S100 calcium
binding protein A8 (S100A8; log2FC Z 7.6; adj.
P Z 2.5  105), S100A9 (log2FC Z 7.0; adj.
P Z 1.5  105), FKBP prolyl isomerase 8 (FKBP8;
log2FC Z 7.3; adj. P Z 3.5  104), keratin 19 (KRT19;
log2FC Z 7.2; adj. P Z 1.4  104), and vesicle-
associated membrane protein 5 (VAMP5; log2FC Z 6.5;
adj. P Z 2.5  103) (Figure 2B). The DEGs are provided
(Supplemental Tables S1 and S2).
Enrichment Analysis of DEGs
To gain more insight into the biological pathways and mo-
lecular functions involved in human CNV formation, a GO
cluster analysis was performed of the 158 DEGs that were up-
regulated in the human CNV membranes. The DEGs
contributed to biological processes, such as blood vessel
development (GO:0001568; 29 counts; adj. PZ 1.7 109),
extracellular structure organization (GO:0043062; 26 counts;
adj.PZ 4.7 1013), immune responseeregulating signaling
pathway (GO:0002764; 16 counts; adj. P Z 0.001), and1636response to wounding (GO:0009611; 21 counts; adj.
P Z 1.8  105) (Figure 2C and Supplemental Table S3).
Molecular function (GO) enrichment analysis showed that the
up-regulated genes were mainly involved in ECM structural
constituent (GO:0005201; 14 counts; adj. P Z 1.5  108),
growth factor binding (GO:0019838; 12 counts; adj.
P Z 3.3  107), cell adhesion molecule binding
(GO:0050839; 20 counts; adj. P Z 5.2  107), integrin
binding (GO:0043236; 7 counts; adj. P Z 0.003), and cyto-
skeletal protein binding (GO:0008092; 23 counts; adj.
PZ 1.1 104) (Figure 2D and Supplemental Table S4). The
top five prominent molecular mediators of the most disease-
relevant biological processes enriched in human CNV are
depicted (Figure 2E). Interestingly, S100A8 and S100A9
emerged as the most prominent DEGs in the immune-related
cluster. All DEGs and CNV-associated genes enriched in the
four most disease-relevant GO biological processes terms are
illustrated in the cnetplot (Figure 3). As expected, a higher
VEGFA (vascular endothelial growth factor A) expression
level was also noted in human CNV membranes compared
with control samples (log2FCZ 0.7); the difference, however,
was not statistically significant.
S100A8/A9 Expression in Human CNV
The RNA-Seq analysis revealed that both the S100A8
(CNV, 42.98 reads; control, 0.05 reads; log2FC Z 7.6; adj.
PZ 2.5  105) and S100A9 (CNV, 166.36 reads; control,
1.41 reads; log2FC Z 7.0; adj. P Z 1.5  105), which
together encode for the S100A8/A9 protein complex cal-
protectin, were significantly increased in human CNV
compared with control tissue (Figure 4, A and B). To
validate these findings on a protein level, S100A9 immu-
nohistochemistry was performed on human CNV mem-
branes and healthy control tissue. In line with the RNA-Seq
results, only a weak S100A9 immunohistochemical stain-
ing was observed in the healthy eye, which was restricted to
a few cells in the lumen of retinal vessels and in the
interstitium of the choroid (Figure 4E). In human CNV
membranes, in contrast, a plethora of S100A9-positive cells
were found that exhibited phagocytic cups, indicating that
these cells belong to the mononuclear phagocyte system
(Figure 4F). Because S100A9 and S100A8 protein form a
soluble and secreted heterodimer protein called calpro-
tectin, a S100A8/A9 enzyme-linked immunosorbent assay
of vitreous samples of patients with nAMD was then per-
formed. The S100A8/A9 heterodimer was significantly
increased in the vitreous of human patients with AMD
(23.21  10.05 ng/mL) compared with that of control
subjects (3.89  0.85 ng/mL; P Z 0.01), strongly sug-
gesting that S100A8/A9 accumulates in the vitreous during
CNV formation (Figure 4C). Conversely, S100A8/A9
protein levels in the plasma of patients with nAMD (1311
 432.8 ng/mL) and control patients (1412  394.8 ng/mL;
P Z 0.79) were not statistically significantly different
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Figure 2 Cell type enrichment analysis of the RNA sequencing data and differentially expressed genes (DEGs) in human choroidal neovascularization (CNV)
membranes compared with age-matched macular retinal pigment epithelium/choroidal tissue. A: Cell type enrichment analysis of the RNA sequencing data
were determined by using xCell, a bioinformatics tool that generates cell type enrichment scores based on gene expression data for 64 immune and stromal cell
types. The heatmap represents the mean enrichment score per group for 12 of the 64 cell types that were differentially enriched (U-test, P < 0.05) in human
CNV versus control tissue. Eight of the 12 cell types are positively enriched, and four are negatively enriched in CNV versus control. B: Volcano plot depicting
the up-regulated and down-regulated DEGs (red and blue dots, respectively) and genes not differentially expressed (gray dots) according to the log2fold
change and the adjusted (adj.) P value. The top 10 DEGs that are increased in CNV membranes are labeled. C and D: Gene Ontology (GO) enrichment analyses
for the 158 DEGs significantly enriched in CNV membranes. Dot plot depicting the top 10 enriched GO terms for biological processes (C) and molecular function
(D) ordered according to the number of DEGs associated with the GO term (count). The size of the dots represents the count, and the dots’ colors represent the
adj. P values. The gene ratio describes the ratio of the count to the number of all DEGs. E: Box plots illustrating the top five factors of the most disease-
relevant GO terms ordered according to log2fold change. CD, cluster of differentiation; NKT, natural killer T cell; Th2, T helper type 2.
Characterization of Human CNV MembranesDiscussion
Deciphering the transcriptional changes and molecular
and cellular mechanisms underpinning human CNVThe American Journal of Pathology - ajp.amjpathol.orgformation is fundamental to understanding and effectively
treating the disease. Advances in genomic technologies,
such as microarrays, RNA-Seq, or whole genome





































































Figure 3 Gene Ontology (GO) enrichment analyses for the 158 differentially expressed genes disclose the potential molecular mediators underlying human
choroidal neovascular membranes. The genes associated with the four most strongly disease-associated Gene Ontology biological processes terms are illus-
trated by the cnetplot, with the size of each node representing the number of overlapped genes in each term and color representing the log2fold change of
each differentially expressed gene.
Schlecht et altranscriptional changes and pathways underlying CNV
formation in patients with AMD.4 The current study is the
first to exploit 30-end RNA-Seq analysis of human CNV
samples fixed in formalin immediately after surgical
extraction, thus reducing the likelihood of bias by RNA
degradation.
The comprehensive RNA-Seq analysis of human CNV
membranes and healthy RPE/choroid revealed considerable
differences in RNA expression levels and cellular compo-
sition between healthy and diseased tissue. A total of
158 differentially expressed transcripts were identified that
were significantly increased in human CNV membranes
compared with control tissue and are critical for three
fundamental processes in CNV pathology: innate immune
system responses, blood vessel development, and wound
healing. The current study emphasizes the prevailing notion
that activation of the innate immune system is associated
with neovascular and scar-forming processes12 and unravels
novel molecular mediators underlying these processes,
which have so far not been linked to nAMD. In agreement
with the literature, the data suggest a critical role of proin-
flammatory M1 macrophages,34,35 T cells,36,37 and natural1638killer T cells38 in the pathogenesis of AMD and CNV, thus
opening new perspectives for cell-specific treatment of
immune-mediated conditions. In particular, evidence for a
significant accumulation of CD4þ T memory cells was
observed in CNV compared with the control samples. These
results are consistent with other studies that found an
increased number of T memory cells in the blood of patients
with AMD compared with non-AMD control samples and
suggest a 13.3-fold increased risk of developing AMD in
patients with elevated blood levels of memory T cells and at
least one CFH H402 risk allele.36
Among the immunomodulatory CNV-associated pro-
cesses, factors such as TSPO,39 LGALS (galectin-1),40 and
CXCL1441 have already been linked to AMD. Others such
as C1r or PVRL2 (nectin-2) have not yet been associated
with AMD and CNV formation, and they require further
investigation. Additionally, several genes involved in blood
vessel development were identified as being overexpressed
in human CNV membranes, thus supporting previous re-
ports.12 Some of these genes, such as APOE,42 Aquaporin
1,43 and HIF2a (EPAS ),44 have already been mentioned in


































































































































Figure 4 Expression of S100 calcium-binding proteins A8 and A9 (S100A8/A9) in human choroidal neovascularization (CNV) membranes compared with
age-matched macular retinal pigment epithelium (RPE)/choroidal tissue. A and B: S100A8/A9 mRNA expression levels in CNV membranes compared with
RPE/choroidal tissue measured by RNA sequencing (RNA-Seq). C and D: S100A8/A9 protein levels in the vitreous and plasma of patients with neovascular
age-related macular degeneration and control (ctrl) subjects measured by using enzyme-linked immunosorbent assay (ctrl, n Z 11; CNV, n Z 7). E and F:
Representative immunofluorescence images for S100A9 (red) and DAPI (white) in CNV membranes and age-matched RPE/choroidal ctrl tissue. Boxed areas
are displayed in higher magnification to the right. Arrows in E indicate S100A9-positive cells in ctrl tissue (most likely granulocytes inside retinal vessels)
and in human CNV membranes. Dotted lines represent vessel wall. Arrowheads indicate S100A9 negative pericytes. Arrow in F indicates a S100A9-positive
cell displaying phagocytic cups. Data are expressed as means  SEM (U-test) (C and D). n Z 4 control, CNV, and RPE/choroidal tissue (A and B); nZ 7 CNV
(C and D); n Z 11 control (C and D). **P < 0.01, ***P < 0.001. Scale bars: 50 mm (E and F, left column); 20 mm (E and F, middle and right columns).
INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer.
Characterization of Human CNV Membranessuch as SFRP1 (secreted frizzled related protein 1) have
previously been associated with neurodegenerative brain
disease.45 The exact role of each of these factors and their
potential as pharmaceutical targets for the treatment of CNV
will need to be investigated in future studies.
Clinical studies and histologic analysis have shown that
CNVmembranes are often associated with excessive wound-
healing responses, resulting in subretinal scarring.46,47 TheseThe American Journal of Pathology - ajp.amjpathol.orgfibrotic processes are characterized by the proliferation and
infiltration of various cell types such as RPE cells, glial cells,
fibroblasts, and innate immune cells contributing to sub-
stantial remodeling of the ECM. In line with this hypothesis,
this study detected many profibrotic and ECM-modulating
factors, including TGF-b1 (transforming growth factor-b1),
FN1 (fibronectin 1), and various collagen types, which are
significantly increased in human CNV membranes. In1639
Schlecht et alparticular, TGF-b is involved in several aspects of subretinal
fibrosis and can induce the expression of collagen-1 and
fibronectin-1, two of the most prominent ECM components
in the course of subretinal fibrosis,48 underscoring the ther-
apeutic potential of this target.49 Other profibrotic factors
such as LGALS9 or VCAN (versican) that were increased in
human CNV membranes in the current study have received
less attention so far and might become future therapeutic
targets.
In search of a soluble and secreted factor that could
constitute an effective drug target, we identified S100A9
among the top DEGs in human CNV membranes. Interest-
ingly, S100A9 was expressed in a plethora of phagocytic
cells (most likely immune cells) in human CNV membranes,
and that the S100A8/A9 protein heterodimer was increased
in the vitreous of human nAMD patients. S100A8/A9 is
constitutively expressed in myeloid cells such as gran-
ulocytes and macrophages, and it acts as a calcium sensor
participating in cytoskeleton rearrangement and arachidonic
acid metabolism under steady-state conditions. During in-
flammatory processes, S100A8/A9 is increasingly expressed
and actively secreted by myeloid cells to modulate the
inflammatory response by stimulating leukocyte recruitment
and cytokine secretion. S100A8/A9 induces Toll-
like receptor 4 or NF-kB signaling and thereby the secretion
of tumor necrosis factor-a, interleukin-1b, or interleukin-6,
which can prolong and exacerbate inflammation.50
Increased levels of S100A8/A9 are a robust feature of
aging and age-related inflammation in mammalian tissues,
including the central nervous system, by activating receptors
for advanced glycation end products, NF-kB, and other
signaling pathways.51 Of direct relevance to AMD, S100
proteins are highly expressed in the macular region of
human donor eyes52 and increased in the Bruch membrane
and choroid complex in human donor eyes with AMD.53
The current study results underline these findings and
reveal S100A8/A9 to be a candidate biomarker for diagnosis
and follow-up of human nAMD, as well as a predictive
indicator of therapeutic responses to inflammation-
associated diseases. Because the pharmaceutical blockade
of S100A8/A9 activity reduces proinflammatory cytokine
secretion and ameliorates excessive inflammation in human
and murine disease, the heterodimer has potential as a
therapeutic target.54e56
This study is limited by its retrospective character and
small sample size. Because the surgical approach entailing
subretinal CNV extraction in patients with nAMD is now
obsolete, a prospective study on human CNV membranes is
not feasible. Furthermore, although the RPE and choroid of
our control group were macroscopically and microscopi-
cally normal, the possibility that the expression profile in
those tissues was altered due to the presence of a ciliary
body melanoma at a distant site in the same eye cannot be
fully excluded. However, because the macula was fundus-
copically unaffected, and the RPE and choroid were
microscopically normal, an effect from ciliary body1640melanoma was considered to be unlikely. Another limitation
of this study is that the bulk RNA-Seq approach used
merely reflects the average gene expression of tissues and,
in contrast to scRNA-Seq studies, cannot reveal important
biological aspects of cell heterogeneity. However, scRNA-
Seq on paraffin sections is not feasible. Instead, bulk RNA
cell type enrichment analysis was used to recover the
identity of the cell types found in human CNV. There are
numerous methods currently available to assess heteroge-
neity in the tissue microenvironment. However, xCell is one
of the most widely used and most robust tools based on the
currently available data within the literature. Recently, a
study systematically analyzed the capacity and limitations of
multiple transcriptome-based cell-type quantification
methods and reported that xCell exhibits correlation indexes
for predicting macrophages and natural killer cells of 0.96
and 0.88, respectively, which is superior to those provided
by other tools (eg, CIBERSORT).57 It is important to note
that the results of cell components were derived from in
silico analysis; these results were not validated via histo-
pathology because of the limited experimental conditions
and sample acquisition difficulties. This limitation needs to
be addressed in future studies. Finally, analysis from the
current study revealed a considerable variability of number
of reads, in particular within the CNV samples. However,
because tissue processing and library preparation were kept
standardized for all samples, it is assumed that the observed
variability is explained by the given biological variability.
In conclusion, gene expression studies by MACE
sequencing in human CNV membranes are feasible and
provide an important initial step to determine the under-
lying cellular and molecular functions in nAMD. This
study reveals novel biomarkers that are increased in
human CNV membranes compared with healthy control
tissue and that contribute to biological processes,
including innate immune activation, ECM organization,
and blood vessel development (Supplemental Figure S2).
Among them, S100A8/A9 has emerged as a promising
biomarker for diagnosis and follow-up of human nAMD.
The transcriptional differences described in this study
provide new insights into the expression landscape of
human CNV pathophysiology and reveal numerous targets
for the development of AMD-directed diagnostics and
pharmaceuticals.
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